Centers for Disease Control and Prevention. HIV Risk Behaviors. Published 2019. https://www.cdc.gov/hiv/risk/estimates/riskbehaviors.html
Chou R, Evans C, Hoverman A, et al. Preexposure prophylaxis for the prevention of HIV infection: evidence report and systematic review for the US preventive services task force. JAMA. 2019;321(22):2214–2230. doi:10.1001/jama.2019.2591
Hillis A, Germain J, Hope V, McVeigh J, Van Hout MC. Pre-exposure prophylaxis (PrEP) for HIV prevention among men who have sex with men (MSM): a scoping review on PrEP service delivery and programming. AIDS Behav. 2020;24(11):3056-3070. doi:10.1007/s10461-020-02855-9
HIV.gov. Pre-Exposure Prophylaxis: PrEP Medication. HIV.gov. Published April 12, 2023. https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis/
Mitchell KM, Dimitrov D, Hughes JP, et al. In what circumstances could nondaily preexposure prophylaxis for HIV substantially reduce program costs?. AIDS. 2018;32(6):809-818. doi:10.1097/QAD.0000000000001766
Nucleoside Reverse Transcriptase Inhibitor (NRTI) | ClinicalInfo. clinicalinfo.hiv.gov. https://clinicalinfo.hiv.gov/en/glossary/nucleoside-reverse-transcriptase-inhibitor-nrti
O Murchu E, Marshall L, Teljeur C, et alOral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022;12:e048478. doi:10.1136/bmjopen-2020-048478
Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the international antiviral society-USA panel. JAMA. 2018;320(4):379-396. doi:10.1001/jama.2018.8431